UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (733) 733
Newsletter (25) 25
Newspaper Article (14) 14
Book Chapter (6) 6
Magazine Article (4) 4
Conference Proceeding (2) 2
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
linagliptin (683) 683
science & technology (453) 453
life sciences & biomedicine (423) 423
humans (316) 316
type 2 diabetes (285) 285
diabetes mellitus, type 2 - drug therapy (244) 244
male (243) 243
diabetes (218) 218
female (169) 169
endocrinology & metabolism (157) 157
dipeptidyl-peptidase iv inhibitors - therapeutic use (151) 151
pharmacology & pharmacy (144) 144
animals (138) 138
middle aged (135) 135
hypoglycemic agents - therapeutic use (128) 128
aged (116) 116
dipeptidyl-peptidase iv inhibitors - pharmacology (109) 109
glucose (109) 109
diabetes mellitus (108) 108
treatment outcome (98) 98
dipeptidyl-peptidase iv inhibitors - adverse effects (90) 90
purines - therapeutic use (90) 90
quinazolines - therapeutic use (90) 90
linagliptin - therapeutic use (89) 89
drug therapy (85) 85
type 2 diabetes mellitus (83) 83
adult (81) 81
metformin (81) 81
research (81) 81
diabetes mellitus, type 2 - blood (80) 80
sitagliptin (76) 76
dpp-4 inhibitor (75) 75
diabetes therapy (71) 71
double-blind method (71) 71
clinical trials (69) 69
drug therapy, combination (69) 69
quinazolines - pharmacology (69) 69
dipeptidyl-peptidase iv inhibitors - administration & dosage (68) 68
saxagliptin (68) 68
analysis (67) 67
care and treatment (67) 67
hypoglycemic agents - administration & dosage (67) 67
purines - pharmacology (67) 67
hypoglycemic agents - adverse effects (66) 66
linagliptin - pharmacology (63) 63
vildagliptin (63) 63
purines - administration & dosage (62) 62
quinazolines - administration & dosage (62) 62
peptidase (61) 61
blood glucose - drug effects (60) 60
insulin (60) 60
dipeptidyl-peptidase iv inhibitors - pharmacokinetics (59) 59
blood glucose - metabolism (58) 58
purines - adverse effects (58) 58
quinazolines - adverse effects (58) 58
dosage and administration (57) 57
hypoglycemic agents - pharmacology (57) 57
risk factors (57) 57
rats (54) 54
dextrose (53) 53
internal medicine (53) 53
mice (53) 53
dipeptidyl peptidase 4 - metabolism (51) 51
hypoglycemia (50) 50
purines - pharmacokinetics (50) 50
quinazolines - pharmacokinetics (50) 50
glycated hemoglobin a - metabolism (49) 49
linagliptin - adverse effects (49) 49
dose-response relationship, drug (48) 48
biological and medical sciences (47) 47
hypoglycemic agents (47) 47
medical sciences (47) 47
alogliptin (45) 45
diabetes mellitus, type 2 - complications (42) 42
cardiovascular system & cardiology (41) 41
drug dosages (41) 41
medical research (41) 41
pharmacokinetics (41) 41
dpp-4 inhibitors (40) 40
glycosylated hemoglobin (40) 40
hyperglycemia (39) 39
medicine (39) 39
dipeptidyl peptidase-4 inhibitor (38) 38
linagliptin - administration & dosage (38) 38
diabetes mellitus, type 2 - metabolism (37) 37
health aspects (37) 37
hypoglycemic agents - pharmacokinetics (37) 37
medicine & public health (37) 37
metformin - therapeutic use (37) 37
chemistry (36) 36
general & internal medicine (36) 36
medicine, general & internal (36) 36
physical sciences (36) 36
complications and side effects (35) 35
medicine, experimental (35) 35
diabetes. impaired glucose tolerance (34) 34
endocrine pancreas. apud cells (34) 34
endocrinopathies (34) 34
hemoglobin (34) 34
patients (34) 34
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (757) 757
Spanish (9) 9
Japanese (7) 7
Czech (6) 6
French (6) 6
Russian (5) 5
Chinese (4) 4
Hungarian (4) 4
German (2) 2
Portuguese (2) 2
Turkish (2) 2
Persian (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JAMA : the journal of the American Medical Association, ISSN 0098-7484, 11/2018, Volume 321, Issue 1, pp. 69 - 79
KIDNEY-DISEASE | MORTALITY | GFR DECLINE | END-POINT | SAXAGLIPTIN | HEART-FAILURE | SITAGLIPTIN | DEATH | OUTCOMES | CKD | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hypoglycemic Agents - therapeutic use | Kidney Failure, Chronic - mortality | Cardiovascular Diseases - etiology | Double-Blind Method | Cardiovascular Diseases - prevention & control | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Middle Aged | Risk Factors | Linagliptin - adverse effects | Proportional Hazards Models | Male | Linagliptin - therapeutic use | Glycated Hemoglobin A | Cardiovascular Diseases - mortality | Female | Aged | Diabetes Mellitus, Type 2 - drug therapy | Drug Therapy, Combination | Hypoglycemia - chemically induced | Hypoglycemic Agents - adverse effects | Diabetes Mellitus, Type 2 - complications | Kidney Failure, Chronic - etiology | Type 2 diabetes | Usage | Clinical trials | Research | Risk factors | Complications and side effects | Analysis | Placebos | Linagliptin | Dosage and administration | Kidney diseases | Cardiovascular diseases | Drug therapy | Myocardial infarction | End-stage renal disease | Adjudication | Risk | Effects | Incidence | Vascular diseases | Hemoglobin | Diabetes mellitus (non-insulin dependent) | Urine | Creatinine | Cerebral infarction | Stroke | Kidneys | Peptidase | Epidermal growth factor receptors | Diabetes mellitus | Pancreatitis | Health risks | Hypoglycemia | Insulin | Patients | Placebo effect | Prescription drugs | Renal failure | Infarction | Adults | Diabetes | Index Medicus | Abridged Index Medicus | Online First | Original Investigation
Journal Article
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, ISSN 1386-1425, 03/2021, Volume 248
Journal Article
Cardiovascular diabetology, ISSN 1475-2840, 03/2018, Volume 17, Issue 1, pp. 39 - 39
Treatment outcome | Diabetes mellitus, type 2 | Dipeptidyl-peptidase IV inhibitors | Diabetic nephropathies | Linagliptin | Research design | Cardiovascular diseases | Clinical trial, phase IV | Cardiac & Cardiovascular Systems | Endocrinology & Metabolism | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Kidney Failure, Chronic - mortality | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Cardiovascular Diseases - drug therapy | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Linagliptin - adverse effects | Diabetic Nephropathies - drug therapy | Male | Linagliptin - therapeutic use | Diabetic Nephropathies - diagnosis | Cause of Death | Renal Insufficiency, Chronic - drug therapy | Glomerular Filtration Rate - drug effects | Time Factors | Cardiovascular Diseases - mortality | Renal Insufficiency, Chronic - mortality | Female | Renal Insufficiency, Chronic - diagnosis | Kidney - physiopathology | Cardiovascular Diseases - diagnosis | Kidney Failure, Chronic - physiopathology | Kidney - drug effects | Double-Blind Method | Risk Factors | Treatment Outcome | Biomarkers - blood | Renal Insufficiency, Chronic - physiopathology | Disease Progression | Diabetic Nephropathies - mortality | Blood Glucose - drug effects | Diabetes Mellitus, Type 2 - diagnosis | Diabetes Mellitus, Type 2 - blood | Diabetes Mellitus, Type 2 - mortality | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Research Design | Index Medicus
Journal Article
Journal Article